Compare Gilead Sciences, Inc. (GILD) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nasdaq Inc — how do they compare? Gilead Sciences, Inc. trades at $133.94 (market cap $163.51B), while Nasdaq Inc trades at $94.82 (market cap $51.67B). The key difference: Gilead Sciences, Inc. is far larger — about 3.2× Nasdaq Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | NDAQ | |
|---|---|---|
Market Cap | $163.51B | $51.67B |
Sector | Health | Financials |
52-Week High | $155.80 | $100.98 |
52-Week Low | $108.22 | $76.85 |
Enterprise Value | $178.05B | $58.73B |
Dividend Yield | 2.49% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Nasdaq (NDAQ) trades at $94.72, up 7.62% with strong bullish momentum. The stock shows robust fundamentals with revenue growth to $8.26B in 2025 and net income margin of 23.03%. Recent earnings beats and a $0.31 dividend signal financial health. Technical indicators show overbought conditions but overall bullish sentiment.
Outlook remains positive with analyst consensus target of $105.60, though risks include market volatility and high valuation multiples. Investment opportunity lies in continued earnings growth and strategic positioning as a leading exchange operator.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
